BillionToOne is a pioneering precision diagnostics company dedicated to transforming healthcare through innovative molecular diagnostics. Focused on prenatal screening and liquid biopsy, the company employs a proprietary molecular counting platform to enhance disease detection by quantifying biological information. This technology enables accurate, rapid, and accessible diagnostics, striving to remove the fear of the unknown for patients.

BillionToOne’s mission emphasizes empowering individuals with precise genetic insights into their health, ensuring that healthcare remains affordable and transparent. Their product offerings revolve around non-invasive prenatal testing that helps expectant parents make informed decisions, as well as advanced liquid biopsy services for cancer detection that are designed to improve early diagnosis.

With a commitment to core values such as creativity, collaboration, and patient-centered care, BillionToOne is revolutionizing the way genetic information is accessed and utilized, putting patients at the forefront of their innovative approach in the healthcare landscape.